Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia (NCT05303792)
A Randomized Phase II Study Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Plus Blinatumomab Compared to Usual Chemotherapy Plus Blinatumomab for Older Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial compares the combination of inotuzumab ozogamicin and low intensity chemotherapy and blinatumomab to the usual chemotherapy with blinatumomab in treating patients with B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a drug, called CalichDMH. Inotuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD22 receptors, and delivers CalichDMH to kill them. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. A monoclonal antibody, such as blinatumomab, is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving inotuzumab ozogamicin with chemotherapy and blinatumomab may help shrink the cancer and stop it from returning.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (72 Sites)
Showing the first 25 of 72 sites.
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Institute Palo Alto — Palo Alto, California
- Yale University — New Haven, Connecticut
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
- Saint Luke's Cancer Institute - Boise — Boise, Idaho
- Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
- Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
- Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
- Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
- Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho
- Northwestern University — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- NorthShore University HealthSystem-Evanston Hospital — Evanston, Illinois
- NorthShore University HealthSystem-Glenbrook Hospital — Glenview, Illinois
- NorthShore University HealthSystem-Highland Park Hospital — Highland Park, Illinois
- Loyola University Medical Center — Maywood, Illinois
- UC Comprehensive Cancer Center at Silver Cross — New Lenox, Illinois
- University of Chicago Medicine-Orland Park — Orland Park, Illinois
- Memorial Hospital East — Shiloh, Illinois
- Northwestern Medicine Cancer Center Warrenville — Warrenville, Illinois
- University of Kansas Cancer Center — Kansas City, Kansas
- University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in B Acute Lymphoblastic Leukemia
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma — Birmingham, Alabama
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia — Birmingham, Alabama
- Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia — Duarte, California
- Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies — Palo Alto, California
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies — Palo Alto, California
Explore by condition: All B Acute Lymphoblastic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.